Allergan PLC. (NYSE:AGN) Shares Bought by Verde Servicos Internacionais S.A.
Verde Servicos Internacionais S.A. raised its stake in shares of Allergan PLC. (NYSE:AGN) by 3.4% during the second quarter, Holdings Channel reports. The institutional investor owned 105,430 shares of the company’s stock after buying an additional 3,453 shares during the period. Allergan PLC. comprises about 5.6% of Verde Servicos Internacionais S.A.’s investment portfolio, making the stock its 3rd largest position. Verde Servicos Internacionais S.A.’s holdings in Allergan PLC. were worth $25,628,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Horan Capital Management increased its position in Allergan PLC. by 21.4% in the first quarter. Horan Capital Management now owns 38,717 shares of the company’s stock worth $9,250,000 after buying an additional 6,836 shares during the period. BKD Wealth Advisors LLC purchased a new position in Allergan PLC. during the first quarter worth $219,000. American National Bank increased its position in Allergan PLC. by 0.6% in the first quarter. American National Bank now owns 15,233 shares of the company’s stock worth $3,640,000 after buying an additional 95 shares during the period. Atria Investments LLC increased its position in Allergan PLC. by 35.1% in the first quarter. Atria Investments LLC now owns 7,310 shares of the company’s stock worth $1,747,000 after buying an additional 1,900 shares during the period. Finally, Cribstone Capital Management LLC increased its position in Allergan PLC. by 3.6% in the first quarter. Cribstone Capital Management LLC now owns 6,803 shares of the company’s stock worth $1,625,000 after buying an additional 236 shares during the period. Institutional investors and hedge funds own 84.77% of the company’s stock.
Allergan PLC. (AGN) traded up 0.29% during midday trading on Friday, reaching $232.88. The company had a trading volume of 1,820,899 shares. The stock’s 50 day moving average is $245.93 and its 200 day moving average is $238.13. The firm has a market capitalization of $77.85 billion, a price-to-earnings ratio of 7.10 and a beta of 1.16. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same quarter in the previous year, the firm earned $3.35 earnings per share. The business’s revenue was up 8.8% on a year-over-year basis. Equities research analysts expect that Allergan PLC. will post $16.27 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be given a $0.70 dividend. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.20%. Allergan PLC.’s dividend payout ratio is currently 9.95%.
AGN has been the subject of a number of recent research reports. Citigroup Inc. reaffirmed a “focus list” rating and set a $261.27 price target (up previously from $184.50) on shares of Allergan PLC. in a research report on Friday, April 21st. Royal Bank Of Canada upped their price target on Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 10th. Goldman Sachs Group, Inc. (The) downgraded Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target for the company. in a research report on Wednesday, May 10th. UBS AG reaffirmed a “buy” rating and set a $275.00 price target on shares of Allergan PLC. in a research report on Monday, May 15th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Allergan PLC. in a research report on Thursday, May 25th. Eight investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $274.49.
In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.36% of the stock is currently owned by insiders.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.